JPWO2020179859A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020179859A5
JPWO2020179859A5 JP2021503643A JP2021503643A JPWO2020179859A5 JP WO2020179859 A5 JPWO2020179859 A5 JP WO2020179859A5 JP 2021503643 A JP2021503643 A JP 2021503643A JP 2021503643 A JP2021503643 A JP 2021503643A JP WO2020179859 A5 JPWO2020179859 A5 JP WO2020179859A5
Authority
JP
Japan
Prior art keywords
group
formula
phenyl
trifluoromethyl
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021503643A
Other languages
English (en)
Japanese (ja)
Other versions
JP7413346B2 (ja
JPWO2020179859A1 (enExample
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/009357 external-priority patent/WO2020179859A1/ja
Publication of JPWO2020179859A1 publication Critical patent/JPWO2020179859A1/ja
Publication of JPWO2020179859A5 publication Critical patent/JPWO2020179859A5/ja
Application granted granted Critical
Publication of JP7413346B2 publication Critical patent/JP7413346B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021503643A 2019-03-06 2020-03-05 ピロロピラゾール誘導体 Active JP7413346B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019040649 2019-03-06
JP2019040649 2019-03-06
PCT/JP2020/009357 WO2020179859A1 (ja) 2019-03-06 2020-03-05 ピロロピラゾール誘導体

Publications (3)

Publication Number Publication Date
JPWO2020179859A1 JPWO2020179859A1 (enExample) 2020-09-10
JPWO2020179859A5 true JPWO2020179859A5 (enExample) 2022-11-11
JP7413346B2 JP7413346B2 (ja) 2024-01-15

Family

ID=72338358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503643A Active JP7413346B2 (ja) 2019-03-06 2020-03-05 ピロロピラゾール誘導体

Country Status (7)

Country Link
US (1) US12240855B2 (enExample)
EP (1) EP3936192B1 (enExample)
JP (1) JP7413346B2 (enExample)
KR (1) KR20210135521A (enExample)
CN (1) CN113543852A (enExample)
TW (1) TW202100526A (enExample)
WO (1) WO2020179859A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022080305A1 (ja) * 2020-10-13 2022-04-21 第一三共株式会社 抗ptdss2抗体
CN114426466B (zh) * 2020-10-29 2023-11-21 江苏和成新材料有限公司 一种醇羟基供体与活性氢供体进行光延反应的方法
US12350241B1 (en) 2024-04-29 2025-07-08 Imam Mohammad Ibn Saud Islamic University Method for inhibiting proliferation of cancer cells

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0395144A (ja) 1989-08-04 1991-04-19 Ono Pharmaceut Co Ltd アミノフェノール誘導体の製造方法
JPH1129540A (ja) 1997-07-04 1999-02-02 Showa Kako Kk エステル誘導体の製造方法
WO1999048880A1 (en) 1998-03-23 1999-09-30 Asahi Kasei Kogyo Kabushiki Kaisha Benzothiazolone-7-sulfonamide derivatives
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
BR0113610A (pt) 2000-08-31 2003-06-24 Pfizer Derivados da fenoxibenzilamina como inibidores seletivos de recuperação de serotonina
TW593329B (en) 2001-02-26 2004-06-21 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and pharmaceutical uses thereof
DK1859798T3 (en) 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
GB0109103D0 (en) 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
JP2003321406A (ja) 2002-04-30 2003-11-11 Mitsubishi Gas Chem Co Inc 高純度フルオロアルキルベンゼン誘導体及びその製造法
US20040132708A1 (en) 2002-05-01 2004-07-08 Wyeth Process for preparing 6-alkylidene penem derivatives
EP1510510A1 (en) 2002-05-31 2005-03-02 Banyu Pharmaceutical Co., Ltd. Method of substituent introduction through halogen-metal exchange reaction
EP2308878A3 (de) 2002-08-21 2011-10-26 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-Amino-Piperidin-1-YL] -Xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
CA2495939A1 (en) 2002-09-04 2004-03-18 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Cathepsin cysteine protease inhibitors
US7256218B2 (en) 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
TW200615273A (en) 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
ES2349110T5 (es) 2004-12-20 2013-11-27 Genentech, Inc. Inhibidores de IAP derivados de pirrolidina
JP4794873B2 (ja) 2005-03-03 2011-10-19 富士フイルムファインケミカルズ株式会社 ハロゲン−リチウム交換反応を用いる有機化合物の製造法
DE602006010834D1 (de) 2005-03-16 2010-01-14 Janssen Pharmaceutica Nv Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
TW200716104A (en) 2005-06-01 2007-05-01 Wyeth Corp Tricyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
BRPI0611620A2 (pt) 2005-06-10 2009-01-13 Boehringer Ingelheim Int mimÉticos de glicocorticàide, mÉtodos de fazÊ-los, composiÇÕes farmacÊuticas e usos dos mesmos
WO2007018956A2 (en) 2005-07-20 2007-02-15 Merck & Co., Inc. Antidiabetic oxazolidinediones and thiazolidinediones
US20070066624A1 (en) 2005-08-16 2007-03-22 Anormed, Inc. Chemokine receptor binding compounds
CN101331120A (zh) 2005-10-13 2008-12-24 史密丝克莱恩比彻姆公司 作为阿片样物质受体调节剂的酚醚化合物
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
AU2007209381A1 (en) 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
WO2007105637A1 (ja) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP2023728A4 (en) 2006-05-26 2010-11-24 Janssen Pharmaceutica Nv OXAZOLYLPIPERIDINES AS MODULATORS OF FATTY ACID AMIDHYDROLASE
ATE520651T1 (de) 2006-10-23 2011-09-15 Pfizer Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
EP2098517B1 (en) 2006-12-01 2013-12-18 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
CN101611023A (zh) 2006-12-14 2009-12-23 大正制药株式会社 1-苯基1-硫代-d-山梨醇衍生物
US8101644B2 (en) 2007-03-30 2012-01-24 Shionogi & Co., Ltd. Pyrrolinone derivative and pharmaceutical composition comprising the same
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US20090227560A1 (en) 2007-04-27 2009-09-10 Takanobu Kuroita Substituted imidazole compound and use thereof
AU2008257145B2 (en) 2007-05-25 2011-11-10 Amgen Inc. Substituted hydroxyethyl amine compounds as Beta-secretase modulators and methods of use
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
WO2009051956A2 (en) 2007-10-16 2009-04-23 E. I. Du Pont De Nemours And Company Pyrazole-substituted isoxazoline insecticides
WO2009058921A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
JP2009120553A (ja) 2007-11-16 2009-06-04 Taisho Pharmaceutical Co Ltd C−フェニルグルシト−ル化合物を有効成分とする糖尿病治療剤
ATE506359T1 (de) 2007-11-30 2011-05-15 Bayer Schering Pharma Ag Heteroaryl-substituierte piperidine
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
JP2009155212A (ja) 2007-12-25 2009-07-16 Taisho Pharmaceutical Co Ltd C−フェニル1−チオグルシト−ル化合物を有効成分とする糖尿病治療剤
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
CA2714743C (en) 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
CA2720096A1 (en) 2008-04-11 2009-10-15 Institute Of Medicinal Molecular Design, Inc. Pai-1 inhibitor
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
US20110053949A1 (en) 2008-04-17 2011-03-03 Pfizer Inc. 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
JP2011518200A (ja) 2008-04-22 2011-06-23 メルク フロスト カナダ リミテツド ステアロイル−補酵素aデルタ−9デサチュラーゼの阻害剤としての新規な置換複素環式芳香族化合物
KR101605576B1 (ko) 2008-05-27 2016-03-22 아스트라제네카 아베 페녹시피리디닐아미드 유도체 및 pde4 매개 질환 상태의 치료에서의 그의 용도
CN102105452A (zh) 2008-05-29 2011-06-22 兴和株式会社 具有环状连接基的取代甲醇化合物
MX2010014172A (es) 2008-07-03 2011-02-22 Amira Pharmaceuticals Inc Antagonistas de receptores de prostaglandina d2.
WO2010006130A2 (en) 2008-07-09 2010-01-14 Envivo Pharmaceuticals, Inc. Pde-10 inhibitors
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2010035727A1 (ja) 2008-09-25 2010-04-01 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2010123599A2 (en) 2009-01-23 2010-10-28 The Board Of Trustees Of The University Of Illinois Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus
PE20120578A1 (es) 2009-02-10 2012-06-17 Abbott Lab Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
US9006454B2 (en) 2009-04-02 2015-04-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
TW201105665A (en) 2009-04-22 2011-02-16 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
GB201016880D0 (en) * 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
US9302991B2 (en) 2010-10-18 2016-04-05 Raqualia Pharma Inc. Arylamide derivatives as TTX-S blockers
WO2012054721A1 (en) 2010-10-22 2012-04-26 Janssen Pharmaceutical Nv Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
TWI396678B (zh) 2010-12-07 2013-05-21 Nat Univ Tsing Hua 二級醇製備方法
WO2012093174A1 (en) 2011-01-07 2012-07-12 Vivalis 1-(6-membered azo-heterocyclic)-2,5-dihydro-1h-pyrrol-2-one derivatives as anti-hepatitis c virus, the pharmaceutical composition thereof and their therapeutic use
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
FR2973487B1 (fr) 2011-03-31 2018-01-26 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Procede et appareil de production d'un gaz de l'air sous pression par distillation cryogenique
US9051333B2 (en) 2011-04-15 2015-06-09 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides
EP2520556A1 (en) 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Radiolabeled amino acids for diagnostic imaging
GB201113689D0 (en) 2011-08-09 2011-09-21 Amakem Nv Novel PDE4 inhibitors
TW201313726A (zh) 2011-09-16 2013-04-01 Actelion Pharmaceuticals Ltd 製造合成之中間體之方法
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
TWI577677B (zh) 2012-04-25 2017-04-11 拉夸里亞創藥股份有限公司 作爲ttx-s阻斷劑之吡咯並吡啶酮衍生物
US8975398B2 (en) 2012-05-11 2015-03-10 Abbvie Inc. NAMPT inhibitors
TWI585088B (zh) * 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
KR102018409B1 (ko) 2012-07-30 2019-09-04 다이쇼 세이야꾸 가부시끼가이샤 부분적으로 포화된 질소 함유 복소환 화합물
JP6225356B2 (ja) 2012-10-31 2017-11-08 ラクオリア創薬株式会社 Ttx−s遮断薬としてのピラゾロピリジン誘導体
JP2016028016A (ja) 2012-12-12 2016-02-25 大日本住友製薬株式会社 オキサジアゾール誘導体とその医薬用途
EP2968358A4 (en) 2013-03-15 2016-08-10 Ariad Pharma Inc NOVEL CHOLINKINASE INHIBITORS
WO2015005429A1 (ja) 2013-07-10 2015-01-15 Meiji Seikaファルマ株式会社 新規pde4阻害剤
EP2905282A1 (en) 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
AP2016009465A0 (en) 2014-04-01 2016-09-30 Pfizer Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
US9944664B2 (en) 2014-04-15 2018-04-17 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
WO2016019588A1 (en) 2014-08-08 2016-02-11 The Broad Institute, Inc. Oxacazone compounds to treat clostridium difficile
WO2016057770A1 (en) 2014-10-08 2016-04-14 Dow Global Technologies Llc Method for coupling a fluorosulfonate compound with an amine compound
US9980945B2 (en) 2015-01-13 2018-05-29 Vanderbilt University Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN105837576B (zh) 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
WO2016148115A1 (ja) 2015-03-16 2016-09-22 第一三共株式会社 ホスファチジルセリンシンターゼ1阻害剤への応答性を予測する方法
AU2016246410B2 (en) 2015-04-10 2020-11-05 Fmc Corporation Substituted cyclic amides as herbicides
MX2017012512A (es) 2015-04-17 2018-02-09 Dow Agrosciences Llc Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
CN104876936B (zh) 2015-05-25 2018-01-30 中国人民解放军第二军医大学 吡咯酮并吡唑类化合物的制备及作为药物的用途
CA2988391C (en) 2015-10-19 2023-05-09 Latvian Institute Of Organic Synthesis Substituted aminoalkylazoles as malarial aspartic protease inhibitors
CN109195965B (zh) 2016-03-01 2022-07-26 普罗佩纶治疗公司 Wdr5蛋白质-蛋白质结合的抑制剂
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
CN110088100B (zh) 2016-11-08 2023-02-17 癌症研究科技有限公司 作为cdc7抑制剂的嘧啶酮衍生物

Similar Documents

Publication Publication Date Title
RU2439068C2 (ru) Модуляторы mglur5
RU2376293C2 (ru) Производные пиридазин-3(2h)-она и их применение в качестве ингибиторов фдэ4
RU2404164C2 (ru) Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
JPWO2020179859A5 (enExample)
JP2005511543A5 (enExample)
JP2007519754A5 (enExample)
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2006500348A5 (enExample)
JP2004504301A5 (enExample)
JP2005511608A5 (enExample)
JP2003528070A5 (enExample)
JP2007507551A5 (enExample)
JP2020516671A5 (enExample)
RU2312105C9 (ru) N-пиразинилфенилсульфонамиды и их применение при лечении опосредованных хемокинами заболеваний
CA2400167A1 (en) Insecticidal anthranilamides
JP2014511869A5 (enExample)
JP2010504280A5 (enExample)
RU2008141509A (ru) Mglur5 модуляторы 1
RU2008108984A (ru) Терапевтический агент от диабета
JP2001526223A5 (enExample)
JP2008526723A5 (enExample)
JP2010532386A5 (enExample)
JP2010505809A5 (enExample)
JP2019537603A5 (enExample)